Business
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
Record Number of 65 Abstracts Showcasing CareDx Innovation Including Data Showing Clinical Utility of AlloSure Kidney to Guide Immunosuppression Management
About this update from Caredx, Inc.
[{"type":"text","content":"\nRecord Number of 65 Abstracts Showcasing CareDx Innovation Including Data Showing Clinical Utility of AlloSure Kidney to Guide Immunosuppression Management \n\n\nExperts Review Advancements in Artificial Intelligence and Molecular Diagnostics During CareDx Symposium\n\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations. CareDx will also be hosting a satellite symposium1 and sponsoring the Women’s Networking Event. The ATC meeting takes place June 3-7 in San Diego, California.\n\n\n\"We are proud to showcase our leadership with our highest-ever number of abstracts at the 2023 Transplant Congress with data that not only validates the performance of AlloSure® and AlloMap® but also demonstrates their clinical utility in the surveillance and management of patients,” said Reg Seeto, CEO and President of CareDx. “We're also excited to have assembled a world-class panel of experts to describe the latest innovations in transplantation including the additive clinical value of incorporating our molecular biomarkers into artificial intelligence tools to drive earlier insights regarding a patient’s risk of rejection for more personalized, preventative care.”\n\n\nNoteworthy Presentations\n\n\nAlloSure Kidney\n\n\n\nAlloSure donor-derived cell-free DNA (dd-cfDNA) and blood gene expression profiling used to guide immunosuppression minimization in patients on belatacept maintenance (B204). AlloSure used for immunologic surveillance of calcineurin inhibitor (CNI) intolerant patients and to guide transition to belatacept therapy (C145).\n\n\n\nTissue gene expression and AlloSure Kidney used to guide treatment in patients presenting with T-Cell Mediated Rejection (TCMR) (oral abstract #73).\n\n\n\nMultinational multi-center validation of a predictive model showing the clinical value of adding AlloSure Kidney to assess patient risk of clinical and subclinical rejection (oral abstract #91).\n\n\n\nAlloSure dd-cfDNA provides less invasive monitoring for allograft function and survival. A combination of AlloSure, serum creatinine and...